Trial · NCT04680975
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score at Week 24 | Week 24 | Analysis was performed on mITT population. Here, overall number of participants analyzed signifies participants with available data for this outcome measure. | score on a scale | MEAN |
| SECONDARY | Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score at Weeks 8, 16, 36, and 52 | Week 8, 16, 36 and 52 | Analysis was performed on mITT population. Here, number analyzed signifies participants with available data for each specified category. | score on a scale | MEAN |
| SECONDARY | Modified Rodnan Skin Score (mRSS) at Week 24 | Week 24 | Analysis was performed on mITT population. Here, overall number of participants analyzed signifies participants with available data for this outcome measure. | score on a scale | MEAN |
| SECONDARY | Forced Vital Capacity (FVC) Level at Week 24 | Week 24 | Analysis was performed on mITT population. Here, overall number of participants analyzed signifies participants with available data for this outcome measure. | liters | MEAN |
| SECONDARY | Physician Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Week 24 | Week 24 | Analysis was performed on mITT population. Here, overall number of participants analyzed signifies participants with available data for this outcome measure. | score on a scale | MEAN |
| SECONDARY | Patient Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Week 24 | Week 24 | Analysis was performed on mITT population. Here, overall number of participants analyzed signifies participants with available data for this outcome measure. | score on a scale | MEAN |
| SECONDARY | Scleroderma Health Assessment Questionnaire-Disability Index (SHAQ-DI) Total Score at Week 24 | Week 24 | Analysis was performed on mITT population. Here, overall number of participants analyzed signifies participants with available data for this outcome measure. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in Modified Rodnan Skin Thickness Score (mRSS) at Weeks 8, 16, 36, and 52 | Baseline, Week 8, 16, 36 and 52 | Analysis was performed on mITT population. Here, number analyzed signifies participants with available data for each specified category. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in Forced Vital Capacity (FVC) Level at Weeks 8, 16, 36, and 52 | Baseline, Week 8, 16, 36 and 52 | Analysis was performed on the mITT population. Here, number analyzed signifies participants with available data for each specified category. | liters | MEAN |
| SECONDARY | Change From Baseline in Physician Global Assessment (Reported by the Physician) Quantified of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Weeks 8, 16, 36, and 52 | Baseline, Week 8, 16, 36 and 52 | Analysis was performed on the mITT population. Here, number analyzed signifies participants with available data for each specified category. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in Patient Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Weeks 8, 16, 36, and 52 | Baseline, Week 8, 16, 36 and 52 | Analysis was performed on the mITT population. Here, number analyzed signifies participants with available data for each specified category. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in Scleroderma Health Assessment Questionnaire-Disability Index (SHAQ-DI) Total Score at Weeks 8, 16, 36, and 52 | Baseline, Week 8, 16, 36 and 52 | Analysis was performed on the mITT population. Here, number analyzed signifies participants with available data for each specified category. | score on a scale | MEAN |
| SECONDARY | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | From first dose administration (i.e., Day 1) of study medication up to 28 days after last dose (i.e., up to 57.5 weeks) | Analysis was performed on safety population which included all participants who received at least 1 dose of belumosudil 200 mg. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04680975/outcomes